英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • alecensa - Treatment Option for ALK+ NSCLC
    ALECENSA is an oral treatment for adults with non-small cell lung cancer (NSCLC) that is caused by an abnormal ALK gene It can be used after surgery to help lower the chance of the cancer coming back, or as treatment if the cancer has already spread to other parts of the body ALECENSA is taken twice daily with food
  • Alecensa: Uses, Dosage, Side Effects Warnings - Drugs. com
    Alecensa (alectinib) is an oral kinase inhibitor that may be used to treat certain types of non-small cell lung cancer (NSCLC) in adults that have been caused by an abnormal anaplastic lymphoma kinase (ALK) gene, specifically to help prevent your lung canc
  • FDA approves alectinib as adjuvant treatment for ALK-positive . . .
    On April 18, 2024, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc ) for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK
  • How Alecensa Works for Non-Small-Cell Lung Cancer (NSCLC) - WebMD
    How Does Alecensa Work for Non-Small-Cell Lung Cancer (NSCLC)? Alecensa is a type of medicine called a kinase inhibitor Kinases are enzymes that work in the body by sending and receiving signals
  • Alectinib Approved as an Adjuvant Treatment for Lung Cancer
    FDA has approved alectinib (Alecensa) as an adjuvant therapy for people with non-small cell lung cancer (NSCLC) who have ALK-positive tumors
  • Alectinib (Alecensa®) - OncoLink
    Information about this kinase inhibitor used in the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic, non-small cell lung cancer
  • Alecensa has survival edge in ALK+ NSCLC, Study Finds
    The expanding number of targeted therapy options for ALK-positive non-small cell lung cancer (NSCLC) has created a new challenge for clinicians and payers: figuring out which one performs best in routine clinical practice A real-world analysis, published online ahead of print in Lung Cancer, suggests that Alecensa (alectinib) continues to deliver a meaningful survival advantage over the older
  • FDA approves Roche’s Alecensa as the first adjuvant treatment . . .
    Alecensa is a highly selective, central nervous system-active, oral medicine created at Chugai, a member of the Roche Group, Kamakura Research Laboratories for people with non-small cell lung cancer (NSCLC) whose tumours are identified as anaplastic lymphoma kinase (ALK) positive
  • Frontline Alecensa Extends Survival in Advanced ALK-Positive . . .
    “Alecensa versus Xalkori in Untreated ALK-positive Non-Small Cell Lung Cancer” by Dr Solange Peters, et al , New England Journal of Medicine “FDA Approves Alecensa as First Adjuvant Treatment for People With ALK-positive Early-Stage Lung Cancer,” Genentech news release, April 18, 2024





中文字典-英文字典  2005-2009